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Abstract
The molecular heterogeneity of human cancer cells at the level of signaling protein activities remains poorly
understood. Using a panel of 64 colorectal (CRC) cancer cell lines the activity status of the MAP kinases Erk1 and
Erk2 was investigated. Erk1/2 activity varied greatly within the CRC cell line panel and was not detectably asso-
ciated with the speed of cell growth in 10 CRC lines analyzed. As expected, mutations in K-Ras or B-Raf were often,
albeit not always, linked to high Erk1/2 activity. The phosphorylation of several known Erk1/2 targets investigated
did not generally reflect Erk1/2 activity in the 10 CRC lines analyzed. However, the reduction of Erk1/2 activity with
MEK inhibitors generally abolished cell growth but only led to an increase of cellular p27Kip1 levels in CRC cells
with high Erk1/2 activity levels. The results indicate that high Erk1/2 activation is utilized by some CRC lines to
override the cell cycle brake p27Kip1, while others presumably rely on different mechanisms in order to inactivate
this important cell cycle brake. Such detailed knowledge of the molecular diversity of cancer cell signaling
mechanisms may eventually help to develop molecularly targeted, patient-specific therapeutic strategies and
treatments.
Findings
The limited knowledge about the heterogeneity of can-
cers on the signaling protein activity level is a major
obstacle for better, individualized cancer therapies with
signal transduction-modulating drugs. It is now well fea-
sible to comprehensively analyze mutations and mRNA
expression changes in tumor biopsies and isolated
tumor cells with high-throughput techniques. By con-
trast, in-depth biochemical analyses of signaling protein
activities are currently all but impossible with patient
biopsy material. However, important insight into the
individual diversity of cancers can be gained by analyz-
ing large panels of cancer cells from a specific tumor
type [1-3].
Erk1 and 2 are multifunctional kinases which are
employed in a very wide range of normal and pathologi-
cal cell types, in many cases in order to regulate cell
proliferation or differentiation [4-6]. However, these
Erks also play, for example, a role in the trans-endothe-
lial migration of some CRC cells [7] and can promote
angiogenesis and invasion [8,9]. The most studied
signaling cascade engaging Erk1/2 is the Ras - Raf -
MEK - Erk pathway that is transmitting the signals of
numerous cell surface receptors. In many tumors,
including CRC, Erk activation is linked to mutations of
Ras GTPases or the S/T kinase B-Raf [10,11]. By con-
trast, cancer-related mutations in MEK1/2 and Erk1/2
appear to be very rare, although different germline
mutations in MEKs have been recently reported in
human cardio-facio-cutaneous disorders [12].
In this study we have analyzed 64 different CRC cell
lines for the activity status of Erk1 and 2 (for origins of
cells see Additional file 1). The aim was to define how
Erk1/2 activity varies in different CRC cells and what
the functional consequences are, if any. Initially, total
cell lysates were generated (detailed methods provided
in Additional file 2) and analyzed by western blotting
for Erk1/2 activation using a phosphoepitope-specific
antibody. This clearly showed a striking heterogeneity in
Erk1/2 phosphorylation on the Thr202/Tyr204 epitope,
a well-established indicator of Erk1/2 kinase activity
levels (Figure 1). Heterogeneity in the activation of Erk1
versus Erk2 was also observed. Aberrant migration of
phospho-Erk1 was observed in one cell line (CoCM-1),
but this was not investigated further, since many pro-
teins in this cell line display an unexpected size (data
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not shown), arguing for a more general defect in the
protein expression or processing machinery, which is
independent of Erk1. To study the causes and functions
of different Erk1/2 activity levels in CRC, 10 cell lines, 5
with high and 5 with low Erk1/2 phosphorylation, were
selected for further analyses.
Ras GTP-loading assays and data base searches http://
www.sanger.ac.uk/genetics/CGP/CellLines indicated that
4 of 5 lines with high pErk1/2 contain a mutation in the
KRAS gene (Figure 2). The fifth cell line, Colo 741, is
mutated in BRAF (V600E). Interestingly, LS 174T cells
show constitutively elevated Ras·GTP levels and harbour
a KRAS(G12D) mutation but display low Erk1/2 activity.
This is indicative of additional factors like, for example,
protein phosphatases that can substantially affect Erk1/2
activity levels. Several other cell lines in the panel
known to have mutations in the KRAS gene (e.g. Colo
320DM, SK-CO-1, SNU-C2B, SW403, SW620, SW837,
SW1116) or BRAF (e.g. HT-29, LS411, RKO) also dis-
play low Erk activity; see also http://www.sanger.ac.uk/
genetics/CGP/CellLines), further supporting a key role
for additional modifiers in determining the activity of
Erk1/2 within a subset of CRC cell lines.
The total Erk1/2 levels are similar in all 10 cell lines.
Unexpectedly, the apparent activity of MEK1/2, analyzed
by western blotting with a pMEK1/2 (pS217/pS221)
antibody, did not correlate well with Erk1/2 activity
(data not shown). We are at present unable to provide a
molecular explanation for this, but a potential reason
could again be the impact of Erk phosphatases, such as
those of the MKP family.
Comparing the growth rates in the 10 cell lines failed
to show any correlation between Erk1/2 activity and
proliferation speed (Figure 3), initially suggesting to us
that relatively low levels of Erk1/2 activation may be suf-
ficient to drive basal cell proliferation in most, if not all,
Figure 1 Phosphorylation of Erk1/2 in 64 CRC cell lines on its key regulatory epitope. Equal amounts of total cell RIPA protein extracts
were analyzed by western blotting with anti-pT202/pY204 (for human Erk1; corresponds to pT183/pY185 in Erk2), which is well established to
reflect the activation state of Erk1/2. C10 extract from the same batch is included on each blot for standardization. Note that numerous proteins
from CoCM-1 cells display aberrant gel migration for reasons unknown to us (T.K. and S.F., unpublished data).
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CRC cells. The high levels of Erk activity observed in
some CRC lines could thus be random fluctuations
without functional consequences, or they may serve
other functions.
In order to address the latter possibility, selected Erk
substrates and targets, including Elk1, Msk1, Myc and
p90Rsk, were analyzed with phosphoepitope specific
antibodies in the 10 CRC lines. It is not possible to per-
form a comprehensive analysis at this point, since more
than 160 substrates and targets of Erk have been
reported so far [13] and phospho-specific antibodies are
not yet available for many of these targets. In all cases
initially tested we failed to detect a perfect correlation
between Erk activation and phospho-levels of potential
target proteins (data not shown), suggesting to us that
probably none of these proteins is an essential substrate
for all CRC lines with high Erk1/2 activity. Clearly, this
does not preclude a functionally important role of the
Figure 2 Comparison of Erk activities with Ras·GTP loading and known mutations in KRAS and BRAF. Ten CRC lines selected for
particularly high or low Erk1/2 activity from the panel in Figure 1 were grouped and analyzed again for Erk1/2 activation (top panel) and total
Erk1/2 expression levels (second panel), as well as Ras activation (third panel) in total cell protein extracts. Ras activation is measured by Ras·GTP
loading using GST-Raf-RBD(1-149) as activation-specific precipitation probe. The list at the bottom summarizes publicly available data on the
mutational status of the KRAS and BRAF genes in these CRC cell lines www.sanger.ac.uk/genetics/CGP/CellLines. Cell lines written in red show
high Erk1/2 activity, cell lines in black contain low Erk activity.
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phosphorylation of these proteins by Erk1/2 in indivi-
dual cases.
p27Kip1 is an important cell cycle regulatory protein
previously discussed as a direct or indirect target of
Erk1/2, with phosphorylation leading to its proteasomal
destruction [14-16]. Therefore, elevations of p27Kip1
phospho-levels may be difficult to monitor in steady
state, but the inhibition of Erk1/2 may lead to a change
in p27Kip1 abundance which would be expected to be
easily detectable.
Indeed, inhibiting Erk activation through the potent
MEK1/2 inhibitor U0126, led to an increased expression
of p27Kip1 in all 5 CRC lines with high Erk activity and
none of the lines with low Erk activity (Figure 4). HRA-
19 cells, which have slightly higher Erk activity than the
rest of the ‘low Erk’ cell lines display a subtle effect on
p27Kip1 expression when treated with U0126.
The simplest explanation for these findings is that a
subset of CRC cells utilizes the strong activation of
Erk1/2 to down-regulate p27Kip1 expression. This may
be mediated by targeting the Thr187 residue on
p27Kip1, which is linked to its ubiquitinylation and
degradation [14-16].
Despite these interesting results, we can, of course, by
no means exclude the possibility that high Erk1/2 activ-
ity is also required to phosphorylate other key substrates
in this subset of ‘high Erk’ CRC cells.
Erk1 and Erk2 boast a plethora of known substrates
[13] and very likely more remain to be detected. In
many cases, the subcellular distribution and expression
levels of both, Erk kinases and their potential substrates,
could determine which substrates are actually becoming
phosphorylated in a specific cell or disease context.
What is a critical Erk substrate in each individual cancer
may thus depend greatly on the specific genetic compo-
sition of that particular tumor.
Nevertheless, from our study it would appear that
down-regulation of p27Kip1 expression is at least a
common, if not ubiquitous occurrence in CRC cells
with high Erk1/2 activity. Similar findings have been
reported in other tumor types [17]. In some genetic
contexts, however, p27Kip1 may not need to be inacti-
vated for tumors to develop, and could possibly even
take on oncogenic functions according to recent results
[18,19].
Interestingly, the absolute expression levels of p27Kip1
do not correlate with Erk activity levels (Additional file
3). Several reasons could explain this finding. Firstly,
p27Kip1 may be differentially localized in different CRC
cells, allowing in some cases only a portion of p27Kip1
to act as a cell cycle break that requires counter-action
by high Erk activity. Secondly, the individual variability
of the overall genetic composition of each tumor cells
could lead to distinct levels of p27Kip1 being tolerated
Figure 3 Growth of ten selected CRC cell lines with either high or low Erk activity analyzed by MTS assay. Cells were cultured in an
excess of growth medium with 10% FBS which was replaced daily to avoid growth reductions due to medium depletion. Cell lines labeled in
red contain high Erk1/2 activity, while cell lines shown in black possess low Erk activity. For clarity, representative error bars are only shown for
the fast growing HCT 116 cells, but omitted for all other cells lines.
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Figure 4 Inhibition of Erk1/2 activation increases expression of p27Kip1 in CRC cells with high basal Erk1/2 activity. Cells were treated
with increasing doses of the MEK1/2 inhibitor U0126 or the compound solvent DMSO at the highest concentration used (m) for 48 hours and
then harvested and analyzed by western blotting. Note that exposure times of blots for individual cell lines are adjusted to obtain signals of
useful strengths. A Erk expression and activity levels upon U0126 treatment of 5 cell lines with high basal Erk activity (left panels) or low basal
activity (right panels). B Effect of U0126 treatment of CRC cells on the expression levels of the cell cycle regulator p27Kip1.
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before a prominent effect on the cell cycle machinery is
elicited.
It is presently unclear whether p27Kip1 is commonly a
direct Erk target in CRC cells with high Erk activity,
although phosphorylation of p27Kip1 by Erk1/2 in CRC
has been suggested and complex formation of endogen-
ous p27Kip1 and Erk1/2 was detected in LoVo cells by
co-immunoprecipitation [20]. Indirect mechanisms of
p27Kip1 regulation by Erk have also been reported [21].
p27Kip1 downregulation through high Erk activity
levels is only one molecular route to eliminate the nor-
mal function of this important cell cycle regulator
[22,23]. Many CRC cells of the analyzed panel with low
Erk1/2 activity have presumably found alternative means
to accomplish this task. This does, of course, not imply
that those cells do not require Erk activity; in fact, as
discussed above, inhibiting Erks close allies, MEK1/2,
clearly reduces Erk activity and inhibits proliferation in
these cells (data not shown).
We also observed that U0126 treatment of CRC cells
led to marked morphology changes in some of the cell
lines (see Additional file 4) further supporting multiple
functional roles of MEK1/2 and, presumably, Erk1/2.
The results reported here imply that different Erk sig-
nal intensities are used in CRC cells to accomplish dis-
tinct molecular tasks, an observation that was also made
in a previous study analyzing the activity of Src family
kinases in this cell line panel [3]. Understanding the
importance of different signal strengths in individual
cancers is not only of interest to learn more about these
still poorly grasped diseases, it may eventually also
impact on the therapeutic use of signal transduction-
modulating drugs. In the case of p27Kip1, which is not
usually mutated in cancers, the inhibition of its protea-
somal degradation could become a useful therapeutic
option for some CRC patients, including those with con-
stitutively high Erk activity.
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